

Notice of OPTN Bylaw Changes

Correction to Primary Pediatric Liver Transplant Program Requirements

Sponsoring Committee:	OPTN Liver and Intestinal Organ Transplantation Committee
Bylaws Affected:	<i>F.4.E.4: Combined Pediatric Gastroenterology/Transplant Hepatology Training and Experience Pathway</i> <i>F.7.C.2.d: Conditional Approval for a Pediatric Component</i>
Board Approved:	June 27, 2022
Effective Date:	June 27, 2022

Purpose of Bylaw Changes

One of the requirements for primary liver physicians is the proposed primary physician must maintain current working knowledge in liver transplantation, which includes the management of pediatric patients with acute liver failure. Inclusion of experience managing pediatric patients with acute liver failure is present in the following pathways:

- 12-month Transplant Hepatology Fellowship Pathway¹
- Clinical Experience Pathway²
- Three-year Pediatric Gastroenterology Fellowship Pathway³
- Pediatric Transplant Hepatology Fellowship Pathway⁴
- Conditional Approval for Primary Transplant Physician⁵

However, it is not included in the Combined Pediatric Gastroenterology/Transplant Hepatology Training and Experience Pathway⁶ and Conditional Approval for a Pediatric Component.⁷ There is no documented reason or explanation for the omission of the language “acute liver failure” from these two pathways.

Proposal History

In December 2020, the OPTN Board of Directors approved new bylaws establishing requirements for transplant programs to transplant candidates less than 18 years old. In order for a program to transplant candidates less than 18 years old, the bylaws require the program to have an approved pediatric component, which requires an approved primary pediatric surgeon and physician. These positions must meet pediatric specific requirements as outlined in the bylaws. These requirements include experience

¹ OPTN Bylaws, F.4.A

² OPTN Bylaws, F.4.B.

³ OPTN Bylaws, F.4.C.

⁴ OPTN Bylaws, F.4.D

⁵ OPTN Bylaws, F.4.F.

⁶ OPTN Bylaws, F.4.E.

⁷ OPTN Bylaws F.7.C.

and current working knowledge in the specific organ. For liver, current experience in managing pediatric patients with acute liver failure was deemed necessary experience in order to become a primary pediatric liver physician.

Summary of Changes

This proposal is to add the language “acute liver failure” to the Combined Pediatric Gastroenterology/Transplant Hepatology Training and Experience Pathway and Conditional Approval for a Pediatric Component pathway. Inclusion of this phrase will ensure that proposed primary pediatric liver physicians have adequate experience in this area and will maintain consistency in experience across the pathways.

Implementation

OPTN members do not need to take any action as a result of the implementation of this proposal.

Affected Bylaw Language

New language is underlined (example) and language that is deleted is struck through (~~example~~).

1 **F. Membership and Personnel Requirements for Liver Transplant Programs and Intestine**
2 **Transplant Programs**

3 [...]

4 **F.4 Primary Liver Transplant Physician Requirements**

5 [...]

6 **E. Combined Pediatric Gastroenterology/Transplant Hepatology Training**
7 **and Experience Pathway**

8
9 A physician can meet the requirements for primary liver transplant physician if the
10 following conditions are met:

11 [...]

12 4. The individual has maintained a current working knowledge of liver transplantation,
13 defined as direct involvement in liver transplant patient care within the last 2 years. This
14 includes the management of pediatric patients with end-stage liver disease, acute liver
15 failure, the selection of appropriate pediatric recipients for transplantation, donor
16 selection, histocompatibility and tissue typing, immediate post-operative care including
17 those issues of management unique to the pediatric recipient, fluid and electrolyte
18 management, the use of immunosuppressive therapy in the pediatric recipient including
19 side-effects of drugs and complications of immunosuppression, the effects of
20 transplantation and immunosuppressive agents on growth and development,
21 differential diagnosis of liver dysfunction in the allograft recipient, manifestation of
22 rejection in the pediatric patient, histological interpretation of allograft biopsies,
23 interpretation of ancillary tests for liver dysfunction, and long-term outpatient care of

24 pediatric allograft recipients including management of hypertension, nutritional
25 support, and drug dosage, including antibiotics, in the pediatric patient.

26 [...]

27 **F.7 Liver Transplant Programs that Register Candidates Less than 18 Years Old**

28
29 [...]

30 **C. Conditional Approval for a Pediatric Component**

31 A designated liver transplant program can obtain conditional approval for a
32 pediatric component if *either* of the following conditions is met:

33 [...]

34 2. The program has a qualified primary pediatric liver surgeon who meets *all* of the
35 requirements described in *Section F.7.A: Primary Pediatric Liver Transplant Surgeon*
36 *Requirements* and a physician who meets *all* of the following requirements:

37 [...]

38 d. The individual has maintained a current working knowledge of pediatric liver
39 transplantation, defined as direct involvement in pediatric liver transplant patient
40 care within the last 2 years. This includes the management of pediatric patients with
41 end-stage liver disease, acute liver failure, the selection of appropriate pediatric
42 recipients for transplantation, donor selection, histocompatibility and tissue typing,
43 immediate post-operative care including those issues of management unique to the
44 pediatric recipient, fluid and electrolyte management, the use of
45 immunosuppressive therapy in the pediatric recipient including side-effects of drugs
46 and complications of immunosuppression, the effects of transplantation and
47 immunosuppressive agents on growth and development, differential diagnosis of
48 liver dysfunction in the allograft recipient, manifestation of rejection in the pediatric
49 patient, histological interpretation of allograft biopsies, interpretation of ancillary
50 tests for liver dysfunction, and long-term outpatient care of pediatric allograft
51 recipients including management of hypertension, nutritional support, and drug
52 dosage, including antibiotics, in the pediatric patient.

53 [...]